Oral mucous membrane of drug delivery is considered to be a promising alternative to the oral route. Sublingual route is a useful when rapid onset of action is desired than orally administered tablets. The objective of this study was to develop the sublingual tablet of captopril and improve its bioavailability. Captopril is the drug of choice in treatment of hypertension crisis or acute heart failure. Improvement of drug absorption and bioavailability was achieved by decreasing the pH of the mouth using citric acid. A 3 2 full factorial design was applied to optimize the formulations. Nine batches were prepared and evaluated to developing and optimizing sublingual tablets of water soluble drug (captopril). The optimization design was used to obtained the concentration of mixture superdisintegrants X 1 (crosscarmellose sodium, crosspovidone and sodium starch glycolate at 1:1:1 ratio) and using microcrystalline cellulose containing silicon dioxide (Prosolv-SMCC®) as a diluent (X 2 ). Disintegration time and t 90 values used as dependent variables for optimization to obtain the desirable optimized formula. According to the results, the selected variables have a strong influence on disintegration time and T 90 of captopril sublingual tablets. The lowest disintegration time (13.04 sec) and t 90 (2.78 min) were showed by sublingual formulations composed of 7.82 % of superdisintegrants combination (X 1 ) with 30.50 % of prosolv-SMCC (X 2 ). So, this formula was chosen as the optimized formula. The F-optimized formula was compared with the marketed tablet pharmaburst® formula. It is clear from the result that the F-optimize formula had a very significant lower disintegration time than Fpharmaburst (12.2 and 16.3 sec respectively), and t 90 (3.2 and 5.0 minute respectively). The pharmacokinetic parameter for the F-optimized showed a significant (P ≤ 0.05) increase in maximum plasma concentration from 180.0 to 286.5ng/mL, and a shortening of the time taken to reach maximum plasma concentration to 45 min in comparison with the marketed tablet. Finally, the F-optimize improved oral absorption of captopril sublingual and a subsequent acceleration of clinical effect, which is favored for hypertensive crises and cardiac disorders.
One of the fruitful results of oral technological advancement in dosage forms is the orally disintegrating tablets (ODTs) as they disintegrate rapidly in the mouth and do not require water for administration. This work employed mixture design approach for developing and optimizing oral disintegrating tablets of a slightly water soluble drug, vardenafil hydrochloride. Three component mixture design was used to optimize the type and concentration of superdisntegrants, crosscarmellose sodium (X 1 ), crosspovidone (X 2 ) and sodium starch glycolate (X 3 ) using water soluble dextrates (Emdex of the ODTs. The lowest disintegration time, wetting time and t 90 were showed by ODTs formula composed of 1.72 % of crosscarmellose in combination with 4.28 % of crosspovidone. So, this formula was chosen as the optimized formula. Stability studies also showed that the optimized formula was stable under accelerated conditions. And, by comparing the selected formula with Prosolv ® ODT G2 as a ready ODT system, it showed faster disintegration time and higher dissolution rate. Hence, the best superdisintegrants to be used with the water soluble dextrates are crosspovidone in combination with crosscarmellose sodium.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.